Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus (Q35989422)

11 August 2017

1 reference

title

Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus (English)

1 reference

11 August 2017

1 reference

2

Greg L Plosker

1 reference

11 August 2017

Katherine F Croom

1

1 reference

PubMed ID

15610062

11 August 2017

language of work or name

1 reference

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

65

1 reference

11 August 2017

1

1 reference

11 August 2017

137-152

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565010-00015

11 August 2017

0 references

cites work

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565010-00015

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565010-00015

Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565010-00015

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

12 December 2020

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease

1 reference

12 December 2020

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

1 reference

12 December 2020

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

12 December 2020

Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease

1 reference

12 December 2020

Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholeste

1 reference

12 December 2020

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

12 December 2020

Activation of Coagulation in Diabetes Mellitus in Relation to the Presence of Vascular Complications

1 reference

12 December 2020

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness

1 reference

12 December 2020

Statins for all patients with type 2 diabetes: not so soon

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes

1 reference

12 December 2020

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

1 reference

12 December 2020

Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant

1 reference

12 December 2020

Atorvastatin affects C-reactive protein levels in patients with coronary artery disease

1 reference

12 December 2020

Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women

1 reference

12 December 2020

Dyslipidemia management in adults with diabetes

1 reference

12 December 2020

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

1 reference

12 December 2020

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.

1 reference

12 December 2020

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia

1 reference

12 December 2020

Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients

1 reference

12 December 2020

Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.

1 reference

12 December 2020

Reducing cardiovascular risk in type 2 diabetes

1 reference

12 December 2020

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Non-HDL cholesterol: into the spotlight

1 reference

12 December 2020

Clinical Pharmacokinetics of Atorvastatin

1 reference

12 December 2020

Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia

1 reference

12 December 2020

Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project

1 reference

12 December 2020

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

1 reference

12 December 2020

The use of atorvastatin treatment in usual care environments: pooled analysis of six prospective, observational studies in 90,535 patients.

1 reference

12 December 2020

Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase

1 reference

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

1 reference

12 December 2020

Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Atorvastatin does not alter the anticoagulant activity of warfarin

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

1 reference

12 December 2020

Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin

1 reference

12 December 2020

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

1 reference

12 December 2020

Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels

1 reference

12 December 2020

Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus

1 reference

12 December 2020

Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo

1 reference

12 December 2020

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

12 December 2020

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

1 reference

12 December 2020

Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia

1 reference

12 December 2020

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

1 reference

12 December 2020

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes

1 reference

12 December 2020

Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study

1 reference

12 December 2020

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

12 December 2020

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides

1 reference

12 December 2020

Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction

1 reference

12 December 2020

C-reactive protein and incident cardiovascular events among men with diabetes

1 reference

12 December 2020

The effect of atorvastatin on platelet function in patients with coronary artery disease

1 reference

12 December 2020

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

1 reference

12 December 2020

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

12 December 2020

Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.

1 reference

12 December 2020

Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia

1 reference

12 December 2020

Diabetes and cardiovascular disease. The Framingham study

1 reference

12 December 2020

Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study

1 reference

12 December 2020

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

12 December 2020

Clinical trials and lipid guidelines for type II diabetes

1 reference

12 December 2020

Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators

1 reference

12 December 2020

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus

1 reference

12 December 2020

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

1 reference

12 December 2020

Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes

1 reference

12 December 2020

Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.

1 reference

12 December 2020

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

12 December 2020

Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.

1 reference

12 December 2020

Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study

1 reference

12 December 2020

Diabetic dyslipidaemia: current treatment recommendations

1 reference

12 December 2020

10.2165/00003495-200565010-00015

Identifiers

DOI

1 reference

PubMed ID

15610062

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15610062